AGAida Gilyadova

Aida Gilyadova

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Aida Gilyadova has a total of 37 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Optically Monitored Multimodal Treatment Incorporating Sequential Photodynamic Therapy for a Congenital Facial Melanocytic Nevus: An Exploratory Case Report with One-Year Follow-Up

    by Polina M. Alekseeva, Daniil M. Kustov, Arkadiy S. Moskalev, Judith J. Meza, Kanamat T. Efendiev, Anastasiya V. Ryabova, Vladimir I. Makarov, Lyudmila Y. Loschenova, Artem A. Shiryaev, Valentina V. Petunina, et al.

    Background/Objectives: Congenital melanocytic nevi in aesthetically important areas are difficult to treat because excision may require extensive surgery and cause scarring. Photodynamic therapy (PDT) may be less traumatic, but data on its use for these nevi are scarce. This exploratory case report evaluated the feasibility, tolerability, and one-year cosmetic outcome of sequential multimodal PDT with optical monitoring for a facial congenital melanocytic nevus. Methods: A 35-year-old woman with a clinically diagnosed 2 × 4 cm congenital melanocytic nevus of the face underwent 15 sessions over eight months. 5-Aminolevulinic acid (topical and sublingual), ethosomal methylene blue, and chlorin e6 were applied sequentially with sonophoresis; two methylene blue sessions were preceded by 440 nm picosecond laser treatment. PDT was performed at 635 and 660 nm (72–200 J/cm2). Video and spectral fluorescence and diffuse reflectance (hemoglobin oxygenation, blood filling) were measured before photosensitizer (PS) application, after accumulation, and after irradiation. The pigmented area was measured on standardized photographs. Results: Fluorescence predominantly increased after PS application and decreased after irradiation, consistent with accumulation and photobleaching. Oxygenation and blood filling showed no consistent treatment-related trends. The pigmented area decreased by 77.8%, from 5.4 to 1.2 cm2. No visible scarring, atrophy, or systemic adverse events occurred; transient erythema and edema resolved spontaneously. Conclusions: This case shows the technical feasibility of the protocol and a marked cosmetic reduction in visible pigmentation, not therapeutic efficacy. The single-case design, combined interventions, and lack of histological verification and a control group preclude conclusions about individual components, mechanisms, and long-term durability and safety.

  • Open Access

    New Concept of Intraoperative Fluorescence Diagnostics for Photodynamic Dosimetry of Tumors Using Chlorin-Based Photosensitizers

    by Kanamat Efendiev, Arkadii Moskalev, Polina Alekseeva, Alexander Borodkin, Alexey Skobeltsin, Vladimir Makarov, Nina Kalyagina, Kirill Linkov, Aida Gilyadova, Olga Shpileva, et al.

    Photodynamic therapy (PDT) with chlorin-based photosensitizers requires real-time monitoring of photosensitizer distribution and photobleaching to guide treatment, yet existing endoscopic fluorescence systems rely on short-wavelength (375–450 nm) excitation that is spectrally incompatible with 660 nm chlorin e6 (Ce6)-PDT, forcing interruption of therapy for diagnostic imaging. We developed VENERA-red-660, a dual-channel endoscopic system using a single 660 nm laser for simultaneous white-light and Ce6 fluorescence imaging (>670 nm detection) without interrupting irradiation. System sensitivity was validated on optical phantoms (Ce6 0.1–5.0 mg/L), and phototheranostics was performed in patients with basal cell carcinoma (n = 5), vulvar intraepithelial neoplasia grade III (n = 3), and peritoneal carcinomatosis (n = 10) using intravenous chlorin-based photosensitizer. Phantom testing showed a linear fluorescence response (R2 = 0.998) down to the lowest tested concentration of 0.1 mg/L. Pre-PDT fluorescence contrast indices confirmed photosensitizer selectivity in all three tumor types, decreasing by 57%, 66%, and 60% after treatment, consistent with photobleaching; continuous intra-PDT monitoring confirmed progressive photobleaching kinetics, and confocal microscopy verified cellular-level Ce6 selectivity. Increased backscattered laser signal after PDT was consistent with treatment-induced changes in tissue optical properties. These pilot findings demonstrate that single-source phototheranostic monitoring is feasible across external and laparoscopic access routes, supporting further evaluation of VENERA-red-660 as a tool for intraoperative PDT dosimetry.


  • Open Access

    Current Approaches and Emerging Strategies in the Treatment of Peritoneal Carcinomatosis

    by Anna Alyasova, Kanamat Efendiev, Igor Reshetov, Dinara Ilyasova, Olga Shpileva, Victor Loschenov, Vladimir Makarov, Evgenia Zakharova, Pavel Karalkin, Yulia Agakina, et al.

    Peritoneal carcinomatosis (PC) is a common, prognostically unfavorable manifestation of advanced gastrointestinal and gynecological malignancies whose treatment is constrained by the blood-peritoneal barrier, which limits drug penetration even when cytoreductive surgery is combined with systemic chemotherapy. This review evaluates current intraperitoneal treatment modalities and emerging technologies for overcoming this limitation, based on recent clinical trials and meta-analyses identified through Scopus and PubMed. We sequentially examine conventional intraperitoneal chemotherapy (IPC); hyperthermic intraperitoneal chemotherapy (HIPEC) in ovarian, gastric, and colorectal cancers, with attention to patient selection and the peritoneal cancer index as determinants of survival benefit; pressurized intraperitoneal aerosol chemotherapy (PIPAC) and its electrostatic precipitation variant (ePIPAC); and photodynamic and photothermal therapy for tumor treatment. Novel strategies are also discussed, including IPC combined with immune checkpoint inhibitors, optical dosimetry, and nanomedicine-based drug delivery as tools for improving treatment precision. Overall, management of PC is transitioning toward a personalized, multimodal approach: HIPEC and PIPAC provide standardized platforms for regional therapy, but future progress depends on integrating advanced drug delivery systems, immunotherapy, and real-time intraoperative monitoring, with standardization of protocols through large multicenter trials remaining a priority for translating these modalities into clinical practice.


  • Open Access

    Photodynamic Therapy Combined with Anticancer Drug Therapy in the Treatment of Malignant Neoplasms

    by Igor Reshetov, Anna Alyasova, Olga Shpileva, Pavel Karalkin, Kanamat Efendiev, Daria Pominova, Victor Loschenov, Dinara Ilyasova, Yulia Agakina, Aida Gilyadova, et al.

    Background: Photodynamic therapy (PDT) has emerged as a powerful minimally invasive modality for cancer treatment. However, its efficacy as a monotherapy is often limited by oxygen dependence and limited light penetration. Combining PDT with systemic anticancer drug therapies offers a promising strategy to achieve synergistic effects and overcome resistance. Objective: This review aims to provide a systematic analysis of the mechanisms and clinical potential of combining PDT with chemotherapy, targeted therapy, and immunotherapy, focusing on recent advancements and nanotechnology-based delivery systems. Methods: A comprehensive literature search was performed using PubMed and Scopus databases. The analysis focused on peer-reviewed studies published over the last 10 years addressing synergistic molecular pathways, co-delivery nanoplatforms, and clinical trial outcomes. Results: The combination of PDT with chemotherapy enhances drug accumulation via vascular photosensitization and can overcome multi-drug resistance. Integration with immunotherapy, particularly immune checkpoint inhibitors and tumor vaccines, triggers immunogenic cell death (ICD), leading to systemic antitumor responses. Nanotechnology provides a versatile platform for the targeted co-delivery of photosensitizers and pharmacological agents, significantly reducing systemic toxicity. Conclusions: Combined PDT–drug regimens demonstrate superior therapeutic efficacy compared to monotherapies. Future clinical translation requires the standardization of dosimetry and the development of multifunctional nanomedicines to enable personalized treatment protocols.